Teleflex Incorporated Introduces the UroLift 2 System With Advanced Tissue Control, a Revolutionary Unified Platform Designed to Treat All Prostate Types

WAYNE, Pa., April 02, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced the upcoming full market release of the Advanced Tissue Control (ATC) feature on its unified UroLift 2 System platform designed for the treatment of benign prostatic hyperplasia (BPH) symptoms in men with all prostate types up to 100g. The UroLift 2 System with Advanced Tissue Control (UroLift 2 ATC) has received FDA clearance, marking a significant advancement in BPH care.

The UroLift 2 System is a market leader and proven minimally invasive treatment for BPH that provides an effective alternative to BPH medications and major surgery.^1,2 The UroLift 2 ATC represents a breakthrough in BPH treatment, with its adaptable design that enables physicians to customize treatments to each patient’s unique anatomy and allows a personalized approach to help maximize effectiveness.

The UroLift 2 ATC System offers physicians enhanced confidence, improved control of obstructive tissue and targeting accuracy through tissue control wings and laser-etched needle markers designed to make tissue manipulation and implant delivery more precise.³ A streamlined delivery system, utilizing one handle per procedure and individual implant cartridges, also ensures increased physician comfort and improves efficiency during the procedure.³

“UroLift 2 ATC optimizes enlarged prostate treatment by providing urologists with unparalleled confidence and customization capabilities,” said Jake Newman, President, The Americas, Teleflex. “The UroLift 2 System with ATC offers a comprehensive solution for BPH care, combining cutting-edge technology with proven clinical outcomes.¹ Our innovative platform streamlines procedures and eliminates the need to transition between platforms during a procedure. Enhanced features, including greater and more consistent implant compression and reduced waste, will help drive outcomes and efficiency in healthcare delivery.”

Brian Wilkins, Vice President of Research and Development for Teleflex Interventional Urology, added, “The UroLift 2 ATC is designed to deliver the same proven effectiveness of the UroLift System, with significant enhancements on a unified UroLift 2 platform. Based on physician feedback, it maintains the efficacy of the UroLift System, improves overall performance, and offers physicians the advantage of efficiently treating a broader range of patients.³ This expanded capability offered by UroLift 2 ATC opens new avenues for patient care.”